Skip to main content
. 2014 Jan 13;99(5):1543–1555. doi: 10.1210/jc.2013-2622

Table 4.

Phase III Clinical Trials of KIs in Patients with DTC and MTC

Cancer Study E/C HR PFS (E/C) Ref.
MTC
    Vandetanib (300 mg/d) Phase III (231/100) 0.46a 30.5/19.3 51
    Cabozantinib (140 mg/d) Phase III (219/111) 0.28b 11.2/4.0 64
DTC
    Sorafnib (400 mg/d) Phase III (207/210) 0.58c 10.8/5.8 66

Abbreviations: E/C, experimental group/placebo group; HR, hazard ratio.

a

95% confidence interval (CI), 0.31–0.69; P = .0001.

b

95% CI, 0.19 to 0.40; P < .001.

c

95% CI, 0.45–0.75; P < .0001.